Dr. Anthony joined the UK Markey Cancer Center after more than two decades of experience in oncology with a special focus on gastrointestinal and neuroendocrine oncology. Dr. Anthony’s clinical interests include drug development clinical trials ranging from Phase I to Phase III.
His past clinical investigative interests have been researching agents targeting specific cellular signaling pathways and injectable radiolabeled compounds. This research resulted in the first scan that uses the injectable radiolabeled compound to visualize NET tumors that are smaller than had ever been thought possible. Thanks to Dr. Anthony’s research, patients can now be treated in a more timely fashion than ever before. He has brought a clinical correlative component to complement the ongoing translational activities at Markey Cancer Center.